SG11202111012QA - Trispecific binding proteins, methods, and uses thereof - Google Patents

Trispecific binding proteins, methods, and uses thereof

Info

Publication number
SG11202111012QA
SG11202111012QA SG11202111012QA SG11202111012QA SG11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA
Authority
SG
Singapore
Prior art keywords
methods
binding proteins
trispecific binding
trispecific
proteins
Prior art date
Application number
SG11202111012QA
Other languages
English (en)
Inventor
Joerg Birkenfeld
Gary J Nabel
Zhi-Yong Yang
Huawei Qiu
Joerg Regula
Edward Seung
Ronnie Wei
Lan Wu
Zhen Xing
Ling Xu
Catherine Prades
Tarik Dabdoubi
Béatrice Cameron
Cendrine Lemoine
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11202111012QA publication Critical patent/SG11202111012QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202111012QA 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof SG11202111012QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831572P 2019-04-09 2019-04-09
EP19306261 2019-10-02
PCT/US2020/027320 WO2020210392A1 (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Publications (1)

Publication Number Publication Date
SG11202111012QA true SG11202111012QA (en) 2021-11-29

Family

ID=72751423

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111012QA SG11202111012QA (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Country Status (13)

Country Link
EP (1) EP3953388A1 (ja)
JP (1) JP2022527994A (ja)
KR (1) KR20210149141A (ja)
CN (1) CN113950484A (ja)
AU (1) AU2020272839A1 (ja)
BR (1) BR112021019915A2 (ja)
CA (1) CA3136821A1 (ja)
CO (1) CO2021014918A2 (ja)
IL (1) IL286929A (ja)
MX (1) MX2021012386A (ja)
SG (1) SG11202111012QA (ja)
TW (1) TW202104261A (ja)
WO (1) WO2020210392A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020076853A1 (en) * 2018-10-09 2020-04-16 Sanofi Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
WO2024077118A2 (en) * 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2808914T3 (es) * 2014-09-04 2021-03-02 Stemcell Tech Inc Complejos de anticuerpo solubles para la activación y expansión de linfocitos T o células NK
ES2808853T3 (es) * 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
JP7146395B2 (ja) * 2014-11-20 2022-10-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ＦｏｌＲ１及びＣＤ３を標的とする二重特異性抗体
TWI726862B (zh) * 2015-01-23 2021-05-11 法商賽諾菲公司 特異性結合ｃｄ３及/或ｃｄ１２３之抗-ｃｄ３抗體，抗-ｃｄ１２３抗體及雙特異性抗體
CA2986592A1 (en) * 2015-06-17 2016-12-22 Genentech, Inc. Anti-her2 antibodies and methods of use
US20180142010A1 (en) * 2015-06-26 2018-05-24 Alexion Pharmaceuticals, Inc. Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
CN117069855A (zh) 2015-10-25 2023-11-17 赛诺菲 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
KR20180134378A (ko) 2016-04-13 2018-12-18 사노피 3특이성 및/또는 3가 결합 단백질
JP2019532017A (ja) * 2016-07-14 2019-11-07 フレッド ハッチンソン キャンサー リサーチ センター がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
CA3078800A1 (en) * 2017-10-10 2019-04-18 Sanofi Anti-cd38 antibodies and methods of use
WO2020076853A1 (en) * 2018-10-09 2020-04-16 Sanofi Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection

Also Published As

Publication number Publication date
KR20210149141A (ko) 2021-12-08
JP2022527994A (ja) 2022-06-07
EP3953388A1 (en) 2022-02-16
WO2020210392A1 (en) 2020-10-15
AU2020272839A1 (en) 2021-12-02
BR112021019915A2 (pt) 2021-12-07
TW202104261A (zh) 2021-02-01
MX2021012386A (es) 2022-01-18
CO2021014918A2 (es) 2021-11-19
CN113950484A (zh) 2022-01-18
IL286929A (en) 2021-10-31
CA3136821A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
IL277398A (en) PD-L1 binding epimers and related uses thereof
PT3443006T (pt) Proteínas de ligação triespecíficas e/ou trivalentes
IL278943A (en) Multi-specificity binding proteins and improvements thereof
EP3452089A4 (en) BISPECIFIC BINDING PROTEINS AND USES THEREOF
ZA201901592B (en) Recombinant binding proteins and their use
EP3655432A4 (en) BINDING PROTEIN 1
IL272553A (en) Proteins that bind D2NKG, 16CD, and EGFR, E-HLA, 4CCR, or 1L-PD
IL268567A (en) BCMA, NKG2D and CD16 binding proteins
IL268755A (en) HER2, NKG2D, and CD16 binding proteins
EP3613772A4 (en) SPECIFIC BINDING MOLECULE FOR LRIG-1 PROTEIN AND ITS USE
IL286929A (en) Tri-specific binding proteins, methods, and their use
EP3689893A4 (en) IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE
IL284664A (en) Multispecific binding proteins
EP3515948A4 (en) COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF
EP3380514A4 (en) GDF131-BINDING PROTEINS AND USES THEREOF
ZA202103259B (en) Modified cas9 protein, and use thereof
EP3705121A4 (en) EMOPAMIL BINDING PROTEIN BINDING AGENT AND ITS USE
EP3689894A4 (en) IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE
EP3882266A4 (en) LRIG-1 PROTEIN SPECIFIC BINDING MOLECULE AND USE THEREOF
IL289145A (en) il1rap binding proteins
IL304317A (en) tgf–beta–rii binding proteins
EP3700571A4 (en) ALK7-BINDING PROTEINS AND USES THEREOF
IL284317A (en) FAB pseudoproteins are multispecific binding proteins
EP4077385A4 (en) CXCL10-BINDING PROTEINS AND USES THEREOF
EP3973550C0 (en) PEPTIDE IONOGEL, COMPOSITION, METHODS AND USES THEREOF